What InFLAMES Research Flagship does

InFLAMES Research Flagship is a publicly funded immunology research consortium jointly hosted by the University of Turku and Åbo Akademi University in Turku, Finland. Established in 2021 as part of the Research Council of Finland's Flagship Programme, the initiative coordinates more than 300 researchers focused on understanding normal and mistargeted inflammatory reactions, with the goal of identifying novel drug targets and diagnostic tools to enable personalised medicine in autoimmune disease, cancer, and severe infections. The flagship does not sell commercial products; instead it operates as a translational research and talent platform.

The technology base is built on a set of co-located core research facilities. Turku PET Centre operates 4 cyclotrons, 26 tracer synthesis hot cells, 8 scanners, and roughly 100 imaging tracers, employing more than 200 staff and investigators. Turku Bioimaging, also the Euro-BioImaging ERIC headquarters, provides around 20 high-end microscopes serving hundreds of users annually. Turku Bioscience Centre offers nine service lines including bioinformatics, cell imaging and flow cytometry, proteomics, screening, genome editing, metabolomics, and single-cell omics. The Drug Discovery Platform develops computational workflows for small-molecule protein-protein interaction modulators, and Auria Biobank supplies more than one million biological samples linked to national health registries through the Centre for Population Health Research.

The business model is government grant funding supplemented by public-private partnership income from biotech and pharmaceutical companies. Core funding flows from the Research Council of Finland's Flagship Programme and a €20.7M grant from the Ministry of Education, Science and Culture for the ImmuDocs National Doctoral Education Pilot (81 doctoral positions across six Finnish universities). Additional funding comes from EU MSCA COFUND for the IMMUFELLOW postdoctoral programme and from foundations (ERC, NIH, JDRF, Novo Nordisk Foundation, Business Finland). Industry engagement runs through the Corporate Corner events programme and direct research collaborations with named pharma partners including Roche, Novartis, Sanofi Genzyme, AbbVie, UCB, MSD, Bayer, Orion, Organon, and Faron, alongside a bench of Finnish biotech SMEs. Distribution of research outputs occurs via collaborative research agreements, contract research, spin-off company formation, and a 92-position doctoral/postdoctoral talent pipeline.

Name

InFLAMES Research Flagship

Legal name

InFLAMES Research Flagship

Website

https://inflames.utu.fi

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

InFLAMES Research Flagship is a publicly funded immunology research consortium jointly hosted by the University of Turku and Åbo Akademi University in Finland, coordinating 300+ researchers to identify novel drug targets and diagnostic tools for personalised medicine through academic-industry partnerships.

Ownership category

akta.pro rank

Product category

Academic Immunology Research Consortium

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Immunology research
• Drug target discovery
• Biomedical imaging services
• Doctoral training programs
• Translational research

Headquarters

HQ city

Turku

HQ country

Finland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Research Council of Finland Flagship Programme Funding: Core funding from the Research Council of Finland's Flagship Programme, which is a government-backed initiative to support large-scale research initiatives in Finland.
2. Public-Private Partnerships: Joint efforts with biotech and pharmaceutical companies to transform immunological research and innovations into economic and societal empowerment, including collaborative research agreements, contract research, and spin-off company launches.
3. ImmuDocs National Doctoral Education Pilot Funding: The Ministry of Education, Science and Culture funded ImmuDocs with 20.7M EUR to train doctoral researchers across immunology, immunology-based drug development, and diagnostics across multiple Finnish universities.
4. EU Marie Skłodowska-Curie Actions Funding (IMMUFELLOW): IMMUFELLOW Postdoctoral Programme is co-funded by the European Union's MSCA, providing full-time three-year postdoctoral positions for immunology-related projects.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

InFLAMES Research Flagship is an immunology-focused R&D consortium that conducts collaborative research on normal and mistargeted inflammatory reactions in health and disease, identifies novel drug targets and diagnostic tools for personalised medicine, and provides open-access fee-for-service use of state-of-the-art research infrastructure (PET imaging, cellular and molecular imaging, multi-omics, biobank, drug discovery) to academic and industry partners. It also runs doctoral and postdoctoral training programmes (ImmuDocs, IMMUFELLOW, InFLAMES Doctoral Module, Postdocs in Flames network) and operates a Corporate Corner academy–industry engagement platform that transforms immunological research into economic and societal impact through public-private partnerships and spin-off companies.

Product overview

InFLAMES Research Flagship is an academic research consortium focused on immunology, jointly operated by the University of Turku and Åbo Akademi University in Finland. It is part of the Research Council of Finland's Flagship Programme and does not offer commercial products or services. The organization provides research infrastructure, doctoral education programs (including the ImmuDocs National Doctoral Education Pilot), postdoctoral researcher networks (Postdocs in Flames/PiF), and collaborative platforms for academia-industry interactions in immunology research. Research activities focus on understanding immune system mechanisms in health and disease, with the goal of developing novel diagnostic and therapeutic tools for personalized medicine in collaboration with biotech and pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

• ImmuDocs: National Doctoral Education Pilot Based on the Immune System - a doctoral education program focused on immunology, immunology-based drug development, and diagnostics
• IMMUFELLOW
• ImmuDocs Doctoral Education Pilot
• Postdocs in Flames (PiF)

Products and services

• Open-Access Research Infrastructure Services
• Collaborative and Contract Research Services
• Population Cohort and Registry Research Services

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

47 partnerships are on record, tiered core and major.

• IMMUFELLOW Consortium (EU MSCA COFUND)coreStrategic or Co-development Partner · 1 January 2026Interdisciplinary and Intersectoral Research Fellowship Programme for Future Leaders in Immunology, co-funded by the European Union's Marie Skłodowska-Curie Actions (MSCA). First call selected 11 postdoctoral researchers (9 at University of Turku, 2 at Åbo Akademi University) for immunology-related projects. Second call opens autumn 2026.
• University of TurkucoreStrategic or Co-development PartnerOne of the two host institutions of the InFLAMES Flagship, providing the majority of research infrastructure, researchers, and academic programmes including the ImmuDocs pilot (59 doctoral positions).
• Åbo Akademi UniversitycoreStrategic or Co-development PartnerThe second host institution of the InFLAMES Flagship, providing additional research capacity and 6 doctoral positions in the ImmuDocs pilot. Contributes Swedish-speaking Finland dimension and international research orientation.
• Turku Bioscience CentrecoreTechnology or IntegrationJoint technology centre of University of Turku and Åbo Akademi University providing advanced core facility services in Bioinformatics, Cell imaging and Flow Cytometry, Proteomics, Screening Unit, Genome Editing, Finnish Functional Genomics, Turku Metabolomics Centre, Protein Structure and Chemistry, Zebrafish and Single Cell Omics.
• Turku PET CentrecoreTechnology or IntegrationOne of the largest and best equipped PET facilities worldwide with 4 cyclotrons, 26 tracer synthesis hot cells, 8 scanners and nearly 100 different imaging tracers. Employs more than 200 staff and investigators combining molecular imaging and clinical research.
• Euro-BioImaging ERICcoreTechnology or IntegrationEuropean research infrastructure consortium for biomedical imaging. Turku Bioimaging serves as the ERIC headquarters and head office of Euro-BioImaging Finland, providing access to world-class imaging services and standards.
• Turku BioimagingcoreTechnology or IntegrationFinland's largest and one of Europe's most sought-after provider of cellular and molecular imaging services, annually serving hundreds of users with approx. 20 high-end microscopes. Coordinates Finnish digital image data management and analysis.
• FICAN West Cancer Research CentrecoreStrategic or Co-development PartnerWestern Finland Cancer Centre is a clinical research unit with extensive experience from Phase 1 through Phase 3 studies, providing clinical trial infrastructure and oncology research capabilities.
• Auria BiobankcoreTechnology or IntegrationFinland's first biobank with over a million samples stored. Auria Clinical Informatics maintains clinical patient data of the Wellbeing services county of Southwest Finland, organised and harmonised for research access.
• Clinical Research Centre (CRC)coreStrategic or Co-development PartnerOffers support and services for investigator-initiated clinical studies at the Turku campus.
• Centre for Population Health ResearchcoreStrategic or Co-development PartnerCoordinates several exceptional long-standing and internationally recognised population cohorts linked to national health registries and biobanks.
• Structural Bioinformatics LaboratorycoreTechnology or IntegrationProvides expertise, modern infrastructure and services in structural biology including X-ray crystallography, structural bioinformatics, drug design and scientific IT solutions with connections to national and European infrastructure networks.
• Drug Discovery PlatformcoreTechnology or IntegrationComputer-dependent drug discovery platform developing a cost-efficient platform for drug discovery, especially targeting protein-protein interactions with small molecules.
• Turku Centre for Disease Modelling (TCDM)coreTechnology or IntegrationResearch and service organisation at the Faculty of Medicine providing state-of-the-art facilities and expertise in studies in experimental animals for both academic and industrial non-clinical research. Part of Biocenter Finland, BF FinGMice, and EATRIS networks.
• Central Animal LaboratorycoreTechnology or IntegrationProvides services to biomedical research by supplying and producing laboratory animals, assisting with experimental procedures, guiding ethical use of laboratory animals, and supporting technical questions regarding use and handling.
• Health Campus TurkumajorStrategic or Co-development PartnerHealth campus ecosystem partner supporting the integration of health-related research, education, and innovation activities in Turku.
• BioCity TurkucoreStrategic or Co-development PartnerJoint initiative of University of Turku and Åbo Akademi University strengthening collaboration in life sciences and molecular medicine across the Turku campus. Hosts the annual BioCity Symposium (35th edition in 2026) and organises research programmes.
• RochemajorStrategic or Co-development PartnerPharmaceutical company collaborating with InFLAMES through the Corporate Corner events programme and visiting professor relationships (e.g., Hans Clevers formerly of Roche Pharma Research and Early Development).
• Sanofi GenzymemajorStrategic or Co-development PartnerPharmaceutical industry partner collaborating on immunological research and innovation within the InFLAMES ecosystem.
• NovartismajorStrategic or Co-development PartnerPharmaceutical industry partner listed as part of the InFLAMES pharma industry partner network.
• AbbViemajorStrategic or Co-development PartnerPharmaceutical industry partner listed as part of the InFLAMES pharma industry partner network.
• UCBmajorStrategic or Co-development PartnerPharmaceutical industry partner listed as part of the InFLAMES pharma industry partner network.
• MSDmajorStrategic or Co-development PartnerPharmaceutical industry partner listed as part of the InFLAMES pharma industry partner network.
• OrionmajorStrategic or Co-development PartnerFinnish pharmaceutical company partner listed as part of the InFLAMES pharma industry partner network.
• Organon FinlandmajorStrategic or Co-development PartnerPharmaceutical industry partner listed as part of the InFLAMES business innovation platform partners.
• FaronmajorStrategic or Co-development PartnerFinnish pharmaceutical company partner listed as part of the InFLAMES business innovation platform partners.
• RadiometermajorTechnology or IntegrationMedical device company listed as part of InFLAMES business innovation platform partners.
• PerkinElmermajorTechnology or IntegrationLife sciences and diagnostics company listed as part of InFLAMES business innovation platform and pharma partners.
• DelSiTechmajorTechnology or IntegrationFinnish biotech company providing silica matrix technology for drug delivery, listed as part of InFLAMES business innovation platform partners. Has active collaborations with InFLAMES researchers.
• KaivogenmajorTechnology or IntegrationFinnish biotech company listed as part of InFLAMES business innovation platform partners.
• Athera BiotechnologiesmajorTechnology or IntegrationSwedish biotech company listed as part of InFLAMES business innovation platform partners.
• SYRINX BioanalyticsmajorTechnology or IntegrationFinnish bioanalytics company listed as part of InFLAMES business innovation platform partners.
• Clinical Research Services Turku (CRST)majorTechnology or IntegrationFinnish clinical research services company listed as part of InFLAMES business innovation platform partners.
• Misvik BiologymajorTechnology or IntegrationFinnish life sciences company listed as part of InFLAMES business innovation platform partners.
• 4PharmamajorTechnology or IntegrationFinnish clinical research services company listed as part of InFLAMES business innovation platform partners.
• ABACUS DiagnosticamajorTechnology or IntegrationFinnish diagnostics company listed as part of InFLAMES business innovation platform partners.
• THL (Finnish Institute for Health and Welfare)majorStrategic or Co-development PartnerFinnish national public health institute listed as part of InFLAMES public partners.
• Finnish Diabetes AssociationmajorStrategic or Co-development PartnerPatient organisation represented in the InFLAMES Steering Group, contributing patient perspective to the flagship's research direction.
• Turku University Hospital (TYKS)coreStrategic or Co-development PartnerMajor university hospital represented in the InFLAMES Steering Group, providing clinical research environment and patient access for translational immunology research.
• City of TurkumajorStrategic or Co-development PartnerMunicipal government represented in the InFLAMES Steering Group, supporting the regional innovation ecosystem and economic development.
• SPARK FinlandmajorStrategic or Co-development PartnerFinnish health innovation platform listed as part of InFLAMES public partners.
• CSC – IT Center for SciencemajorTechnology or IntegrationFinnish national IT center for science providing HPC and data infrastructure services, listed as part of InFLAMES research and infrastructure partners.
• Biocenter FinlandmajorTechnology or IntegrationNational Finnish biocenter network listed as part of InFLAMES research and infrastructure partners.
• ImmuDocs Consortium (Ministry of Education and Culture funded)coreStrategic or Co-development PartnerNational Doctoral Education Pilot funded with 20.7M EUR by the Ministry of Education, Science and Culture. Consortium includes University of Turku (59 positions), Åbo Akademi University (6), University of Helsinki (10), University of Oulu (2), University of Eastern Finland (2), University of Tampere (2), Wellbeing Services County of Southwest Finland, and Finnish Vaccine Research.
• Turku Clinical Biomaterials Centre (TCBC)majorStrategic or Co-development PartnerResearch centre listed as part of InFLAMES research and infrastructure partners, supporting biomaterials research in the Turku campus.
• Wellbeing Services County of Southwest FinlandmajorStrategic or Co-development PartnerRegional health authority represented in the InFLAMES Steering Group and part of the ImmuDocs consortium, providing clinical data and healthcare system integration.
• GenentechmajorStrategic or Co-development PartnerRoche subsidiary listed as part of InFLAMES visiting professor programme, with SVP Research Biology Andy Chan serving as InFLAMES Visiting Professor.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Institut Pasteur: One of the world's largest biomedical research organizations with substantial immunology research capacity, broad public funding, and significant industry partnership infrastructure. Comparable as a large public-funded immunology and infectious disease research ecosystem.

Direct peers

• Max Planck Institute for Immunobiology and Epigenetics: Major European immunology research institute with strong academic-industry translational focus. Comparable in scale and mission as a top-level immunology R&D cluster combining basic research with pharma and biotech partnerships.
• Ragon Institute of MGH, MIT and Harvard: Major immunology institute focused on immunology and translational research with deep pharma and biotech industry partnerships. Comparable scope of large immunology talent pool, multi-university backing, and academy-industry integration model.
• La Jolla Institute for Immunology (LJI): Non-profit immunology-focused research organization with strong pharma partnerships and world-class immunology faculty. LJI's mission, scientific focus, and academy-industry interface closely mirror InFLAMES' model; LJI leadership is also represented on InFLAMES' SIAB.
• Karolinska Institutet (Department of Microbiology, Tumor and Cell Biology): One of Europe's leading immunology research institutions. Karolinska's immunology department focuses on translational immunology, hosts analogous academic-industry partnerships with pharma, and operates comparable doctoral training programs. Directly comparable in mission (immunology R&D with pharma integration) and scale.
• Walter and Eliza Hall Institute of Medical Research (WEHI): Australia's leading immunology and translational research institute with deep pharma partnerships and dedicated immunology research programs. Comparable in mission, focus on immunology-driven drug discovery, and strong public-private partnership model.
• Allen Institute for Immunology: A leading immunology research institute with deep focus on human immune system dynamics and clinical-translational immunology partnerships. Comparable in disease-focus (autoimmune, inflammatory diseases) and emphasis on longitudinal cohort-based immunology research.

Others

• Euro-BioImaging ERIC: European research infrastructure consortium for biomedical imaging headquartered at Turku Bioimaging, one of InFLAMES' core infrastructure partners. Comparable as a publicly-funded life sciences infrastructure provider serving academic and commercial users.
• BioCity Turku: Joint life sciences research umbrella organization of University of Turku and Åbo Akademi University that co-hosts the BioCity Symposium with InFLAMES. Closely intertwined ecosystem partner sharing infrastructure and researchers with InFLAMES.

Regional players

• Singapore Immunology Network (SIgN, A*STAR): Public-funded immunology research consortium with extensive industry partnerships across Asia and globally. Comparable in scale and emphasis on human immunology, translational medicine, and pharma partnerships; serves as Asia's regional counterpart to European flagship programs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCy6HfxYDwV8Z6_1Z3fqM0YQ
• LinkedInlinkedin.com/company/inflames-research-flagship

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InFLAMES Research Flagship